Physician profile
Albert L Fullerton
NPI 1205822905
$8,501.48
in general payments reported to CMS, 2019-2025
42 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $229 · 2021: $845 · 2022: $1,972 · 2023: $1,246 · 2024: $1,662 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,816.00 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,065.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $775.23 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $623.75 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $477.95 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Celgene Corporation | $469.53 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $365.45 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $337.91 | 2019-2025 | Nuplazid |
| Mdd US Operations, LLC | $321.38 | 2019-2025 | Apokyn, Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $317.19 | 2019-2025 | Rytary, Crexont, Ongentys |
| Kyowa Kirin, INC. | $279.63 | 2020-2024 | Nourianz |
| Lundbeck LLC | $266.75 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $256.37 | 2020-2025 | |
| Avanir Pharmaceuticals, INC. | $250.08 | 2019-2022 | |
| Genzyme Corporation | $247.72 | 2019-2025 | |
| Eisai INC. | $213.96 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Fullerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.